On December 28th, 2021 the FDA authorized, for the first time, outpatient use of COVID-19 convalescent plasma. The announcement letter can be found here. 

As COVID-19 surges in the United States and around the world, we want to reiterate the following statements:

  •  Sign the petitions:
    • Open letter to WHO for revisions to CCP recommendations. The WHO letter with the first signatories can be found here. The petition can be found here.
    • Open letter to NIH for revisions to CCP recommendations.  The NIH Research Committee letter with the first signatories can be found here. The petition can be found here
  • Convalescent plasma remains under EUA in the United States.
  • Convalescent plasma is more effective when used early in treatment, research highlighting this can be found here and here
  • Local convalescent plasma is preferable to distantly sourced convalescent plasma.
  • The COMPILE statistics team (members of the Division of Biostatistics at the Department of Population Health, and New York University Grossman School of Medicine) built a COVID-19 Convalescent Plasma treatment index tool to guide treatment decisions. The tool can be found in the Health Care Providers section of this website.